BRCA2 and familial pancreatic carcinoma: Using CAPAN1 cells, a pancreatic cancer cell line harboring mutant BRCA2, it was previously shown that cisplatin selection can promote secondary mutations that lead to a restoration of the BRCA2 reading frame and subsequent resistance to cisplatin and PARPi (34).